How Semaglutide Works for Weight Loss:Benefits, Dosage, Side Effects & More

The recent July 2026 study reveals that the hype of GLP-1 drugs on the internet has risen 25-fold over the last decade. In the United States alone, semaglutide carries a search volume of 368.0K at the time of writing.

So, what is it all about? Let’s tell you everything!

Semaglutide and Its Mechanism for Weight Loss

Semaglutide is a prescription medication used to treat type 2 diabetes and for chronic weight management.

Semaglutide belongs to a class of medicines called GLP-1 receptor agonists. These drugs mimic the function of your body’s natural GLP-1 hormone. Because GLP-1 is an incretin hormone, its effects are closely linked to blood glucose levels. It works through several interconnected pathways involving your brain, stomach, pancreas, and appetite-regulation system.

After food intake, GLP-1 is released from the gut and signals the brain to promote feelings of fullness and reduce hunger. It also helps regulate blood sugar levels and slows stomach emptying.

Natural GLP-1 has a half-life of only about 1 to 2 minutes because enzymes in the body break it down quickly.

When you follow a calorie-restricted diet during your weight loss journey, you may experience increased hunger signals and cravings over time.

Semaglutide provides a longer-lasting way to activate GLP-1 receptors and help regulate hunger and food intake.

Semaglutide is designed to mimic GLP-1 while remaining active in the body for much longer, which is why it can be administered once weekly. It works through several pathways, including:

• Influencing the pancreas to increase glucose-dependent insulin secretion and reduce glucagon secretion when blood glucose is elevated, helping regulate blood sugar levels.
• Reducing appetite and food intake by acting on areas of the brain involved in appetite regulation.
• Increasing feelings of fullness and satiety.
• Slowing gastric emptying, which can contribute to feeling full for longer.

Some people may experience gastrointestinal side effects as these effects occur, including nausea, bloating, feeling overly full, abdominal discomfort, vomiting, and constipation.

The effect on gastric emptying is only one part of how semaglutide works. Its effects on appetite and energy intake are also important contributors to weight loss.

Where Does Semaglutide Come From?

Semaglutide is a modified version of the human GLP-1 hormone. Its peptide backbone is produced through yeast fermentation and then chemically modified so it lasts longer in the body.

Work on what became semaglutide began in 2002 at the Danish pharmaceutical company Novo Nordisk. A research team led by chemists Thomas Kruse and Jesper Lau, with technician Paw Bloch and under the scientific leadership of Lotte Bjerre Knudsen, spent several years developing a version of GLP-1 that could be taken just once a week.

Scientists at Novo Nordisk modified the human GLP-1 sequence and attached a fatty acid chain. This allows the drug to bind to blood albumin and resist breakdown, extending its half-life from a couple of minutes to about a week.

Semaglutide was first approved by the FDA on December 5, 2017, under the brand name Ozempic® for type 2 diabetes. On June 4, 2021, it was also approved under the brand name Wegovy® for chronic weight management in adults with obesity or overweight.

Semaglutide is also available in compounded versions, prepared by licensed compounding pharmacies. Compounded semaglutide is available only by prescription from a licensed healthcare provider in the USA, based on your individual health needs.

How Long Does Semaglutide Take to Work?

You may notice changes in appetite before you notice major changes on the scale. Some people experience reduced hunger during the first few weeks.

However, the starting dose is intentionally low to check your tolerability. From there, the dose is gradually increased if your body is adjusting well.

A simple timeline:

• Week 1–2: Appetite may start to decrease, and you may feel fuller for longer.
• Weeks 3–4: Changes in hunger and portion sizes may become more noticeable. Some people begin seeing changes on the scale.
• Months 2–3: Weight loss may become more consistent as the dose is gradually increased.
• Months 4–6: Many people see more noticeable changes in weight, especially when medication is combined with healthy eating and regular activity.
• 6+ months: Weight loss can continue with ongoing treatment, although the pace varies from person to person.

Based on our patient experience, many Ongo patients have reported progress within a similar timeframe. However, individual results vary based on factors such as starting weight, dose, treatment duration, diet, activity level, and response to treatment.

How Much Does Semaglutide Cost?

The cost of semaglutide can vary considerably. Factors may include:

• Brand-name medication vs. compounded semaglutide
• Insurance coverage
• Manufacturer savings programs
• Consultation fees
• Pharmacy pricing
• Dosage
• Treatment duration
• State and provider requirements

If you're considering treatment through a telehealth provider, look beyond the advertised medication price and check whether the total cost includes the medical consultation, prescription, follow-up care, medication, shipping, and ongoing monitoring. At Ongo Weight Loss, eligible patients can access a semaglutide medication and care plan starting at $179. View Ongo Weight Loss Pricing ↗

How Much Weight Can You Lose with Semaglutide?

Many Ongo patients have seen meaningful progress with treatment (up to 15%). Again, weight-loss results vary from person to person. Your results can depend on:

• Starting weight
• Dose
• Treatment duration
• Diet
• Physical activity
• Medical conditions
• Other medications
• Genetics
• How your body responds to treatment
• How consistently treatment is followed

In clinical trials, adults without diabetes who took once-weekly semaglutide 2.4 mg alongside lifestyle changes lost an average of about 15–17% of their body weight over 68 weeks, compared with about 2–6% in the placebo groups. In adults with type 2 diabetes, average weight loss was lower, about 9.6%. These are averages, not guarantees of individual results.

Some people lose more.

Some lose less.

And some people may not respond adequately to treatment.

Semaglutide vs. Traditional Dieting

Because semaglutide may make you feel full sooner, you may naturally eat smaller portions. This can make it especially important to focus on nutrient-dense foods rather than simply eating as little as possible.

Consider building meals around:

• Protein-rich foods: Eggs, fish, poultry, lean meats, Greek yogurt, beans, lentils, and other protein sources
• Fiber-rich foods: Vegetables, fruits, legumes, whole grains, and other high-fiber foods
• Healthy fats: Avocado, nuts, seeds, and other sources of unsaturated fats
• Whole or minimally processed foods: These can provide important vitamins, minerals, and other nutrients
• Adequate fluids: Staying hydrated is particularly important if you experience vomiting, diarrhea, or reduced food and fluid intake

What Foods Should You Avoid With Semaglutide?

There is no universal list of foods that everyone taking semaglutide must avoid.

However, some people find that very large, greasy, or high-fat meals can make gastrointestinal symptoms such as nausea, bloating, reflux, or stomach discomfort worse.

If you notice that certain foods consistently trigger symptoms, consider reducing them.

If you are still running into challenges, our licensed nutritionists and doctors can create a personalized plan to support long-term weight management.

Talk with a nutritionist↗

Semaglutide and the Calorie Deficit

It’s true that you’ll be going into a calorie deficit as you’ll eventually eat less. So, does it mean it’s a better approach than traditional dieting?

Some studies report around 10–13% weight loss with semaglutide over 6 months, while traditional dieting approaches, including intermittent fasting, often result in less weight loss over the same period, commonly around 5–10%. However, results can vary from person to person depending on the approach and how consistently it is followed.

Whether you continue semaglutide long term or eventually stop, you might be wondering what happens to your eating habits over time.

People who are on semaglutide for weight loss often eat fewer calories after 60 weeks. In other words, your eating patterns and diet approach may change. And there’s a 2026 study conducted by Penn Medicine.

“Many patients worry that their medication has stopped working if they notice some return of hunger after the first several months…Our findings show that even when people feel some of those sensations returning, semaglutide continues to help them eat less. That sustained reduction in calorie intake appears to be a key reason why weight loss is maintained over time,” said Jena S. Tronieri, PhD, lead author of the study.

Semaglutide can help reduce appetite and calorie intake, but long-term weight management may involve medication, lifestyle changes, or both.

This is also something we have observed in our clinical experience. Some patients are able to maintain part of their weight loss after treatment, particularly when they continue healthy eating and regular physical activity. However, individual outcomes vary.

Semaglutide and Exercise

Regular exercise can help support:

• Muscle strength
• Cardiovascular health
• Physical function
• Energy expenditure
• Long-term weight management
• Overall health and well-being

Your activity plan can include a combination of aerobic and resistance exercises.

Aerobic activities like walking, cycling, swimming, jogging, dancing, and other activities that increase your heart rate

Resistance training like bodyweight exercises, resistance bands, free weights, and weight lifting for maintaining muscle strength and lean mass. If you are new to exercise, start gradually and increase your activity as your fitness and tolerance improve. Check Latest Workout Plans↗

Semaglutide Dosage for Weight Loss

Semaglutide for chronic weight management is generally started at a low dose and gradually increased.

For the FDA-approved Wegovy® injection, the typical dose-escalation schedule is:

Your healthcare provider may adjust the schedule depending on your response and side effects.

Do not increase your semaglutide dose on your own.

A higher dose is not automatically a better dose. That’s why Ongo Weight Loss and many other trusted medical weight loss providers offer a low-dose approach to semaglutide. Read Semaglutide Dosing Guide↗

How Is Semaglutide Administered?

Semaglutide for weight management is available in two forms: a once-weekly subcutaneous injection and a once-daily oral tablet. Depending on the specific product, injection sites may include:

• Abdomen
• Thigh
• Upper arm

Follow the administration instructions provided with your prescription and medication. Read how to inject a dose from a semaglutide vial.

Who Can Take Semaglutide for Weight Loss and Who Cannot?

Whether semaglutide is appropriate for weight loss depends on your age, weight status, medical history, current medications, and overall health.

For FDA-approved weight-management products such as Wegovy®, treatment may be appropriate for eligible adults with obesity or adults with overweight and at least one weight-related health condition. Certain adolescents with obesity may also qualify.

Semaglutide is not appropriate for everyone. Certain medical conditions, medications, allergies, and other factors may make treatment unsuitable or require additional precautions.

A healthcare provider should review your health history and treatment goals before prescribing semaglutide.

Want to check whether you may qualify? See our complete [Semaglutide Eligibility Guide] for the eligibility criteria, contraindications, and factors providers consider before treatment.

What Happens When You Stop Semaglutide?

Stopping semaglutide does not necessarily mean that your weight will remain at its lowest point.

Semaglutide helps regulate appetite and food intake while you are taking it. After treatment is discontinued, some people may experience increased hunger or changes in appetite, which can make maintaining weight loss more difficult.

Weight regain after stopping semaglutide has been documented in clinical research.

In an extension of the STEP 1 trial, participants who stopped semaglutide after 68 weeks regained a substantial portion of the weight they had previously lost during the following year.

This does not mean that everyone will regain the same amount of weight. Individual outcomes can vary depending on factors such as eating patterns, physical activity, metabolic health, and the reason treatment was discontinued.

Can You Maintain Weight Loss After Stopping Semaglutide?

Some people may maintain part of their weight loss after discontinuing treatment, particularly when they continue healthy eating habits and regular physical activity.

However, weight regain is common after stopping anti-obesity medication. This is one reason weight management is often considered a long-term process rather than a short-term intervention.

If you are thinking about stopping semaglutide, discuss your options with your healthcare provider. Do not stop or change your semaglutide dose without medical guidance.

Semaglutide and Other Medications

Always tell your healthcare provider about all medications and supplements you are taking. This is particularly important if you are taking:

• Other GLP-1 medications
• Insulin
• Certain diabetes medications
• Medications that affect blood glucose
• Other prescription medications

Do not combine semaglutide with another GLP-1 receptor agonist unless specifically directed by your healthcare provider.

Semaglutide vs. Ozempic® vs. Wegovy®: What’s the Difference?

This can get confusing because semaglutide is the active ingredient in both Ozempic® and Wegovy®. The important differences are their FDA-approved indications, formulations, concentrations, dosing protocols, and labeling.

Compounded Semaglutide

Compounded semaglutide is a pharmacy-prepared formulation of semaglutide made for an individual patient or under applicable compounding requirements. Depending on the formulation and pharmacy, it may contain additional inactive ingredients used to create or stabilize the preparation.

Unlike FDA-approved products such as Ozempic® and Wegovy®, compounded semaglutide does not have FDA-approved labeling as a finished drug product. The concentration and formulation can also vary between pharmacies, so the prescribed dose and injection volume may differ from one compounded product to another.

Wegovy®

Wegovy® (semaglutide) is a brand-name medication manufactured by Novo Nordisk. It contains semaglutide in specific FDA-approved formulations and strengths, along with inactive ingredients specified in its prescribing information.

Wegovy® is FDA-approved, along with a reduced-calorie diet and increased physical activity, for chronic weight management in eligible patients. It is also approved for certain cardiovascular risk-reduction indications in adults with established cardiovascular disease who have overweight or obesity.

Ozempic®

Ozempic® (semaglutide) is also manufactured by Novo Nordisk and contains semaglutide in specific FDA-approved formulations and strengths. However, it has different FDA-approved indications from Wegovy®.

Ozempic® is FDA-approved for improving blood sugar control in certain adults with type 2 diabetes. It is also approved for certain cardiovascular and kidney-related risk-reduction indications in adults with type 2 diabetes.

Semaglutide Side Effects

Like any prescription medication, semaglutide can cause side effects. Most commonly reported side effects involve the digestive system and may be more noticeable when treatment is started or when the dose is increased.

Common side effects may include:

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Abdominal pain
• Bloating
• Feeling unusually full
• Indigestion
• Burping
• Headache
• Fatigue
• Dizziness

These effects can vary from person to person. Some people may experience only mild symptoms, while others may have more noticeable gastrointestinal effects.

Nausea, vomiting, diarrhea, and constipation are particularly common during dose escalation. For many people, these symptoms become easier to tolerate as the body adjusts to treatment.

Serious Side Effects and Warnings

Although many semaglutide side effects are mild and gastrointestinal, the medication also carries important warnings and precautions. Depending on the specific semaglutide product, these may include:

• Thyroid C-Cell Tumor Risk (Boxed Warning)
• Pancreatitis
• Gallbladder Problems
• Dehydration and Kidney Problems
• Low Blood Sugar
• Severe Gastrointestinal Reactions
• Allergic Reactions

[Read Important Safety Information↗]

Semaglutide vs. Tirzepatide

Semaglutide and tirzepatide are prescription medications used for weight management in eligible patients. Both can reduce appetite and food intake, but they work through different hormonal pathways.

Semaglutide is a GLP-1 receptor agonist. It mimics the effects of the naturally occurring hormone GLP-1, which helps regulate appetite, slows gastric emptying, and supports glucose-dependent insulin secretion.

Tirzepatide works on two hormone pathways: GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). By activating both receptors, tirzepatide can affect appetite, food intake, blood glucose regulation, and other metabolic processes.

The medications also have different dosing schedules, FDA-approved products, contraindications, and prescribing considerations. Clinical studies have reported substantial weight loss with both medications, but results vary by study design, dose, treatment duration, and individual patient factors.

The right medication depends on your health history, treatment goals, current medications, eligibility, and how you respond to treatment. A healthcare provider can help determine which option is appropriate for you.

For a more detailed comparison, see [Semaglutide vs. Tirzepatide].

Bottom Line

Semaglutide can be an effective option for people who need medical support with weight management. By mimicking GLP-1, it can help regulate appetite, increase feelings of fullness, reduce food intake, and support better blood sugar control. However, results vary from person to person, and treatment should be personalized based on your health, goals, and response to medication. Along with semaglutide, healthy eating, regular physical activity, and ongoing medical guidance can support sustainable, long-term weight management.

References

1. U.S. Food and Drug Administration. Wegovy® (semaglutide) prescribing information [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2026. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s030lbl.pdf

   Wegovy prescribing information — FDA

2. U.S. Food and Drug Administration. Ozempic® (semaglutide) prescribing information [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2026. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209637s038lbl.pdf

   Ozempic prescribing information — FDA

3. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183. Available from: https://doi.org/10.1056/NEJMoa2032183

   Full article — New England Journal of Medicine

4. Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725. Available from: https://doi.org/10.1111/dom.14725

   Full article — Diabetes, Obesity and Metabolism

5. Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomized, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984. doi:10.1016/S0140-6736(21)00213-0. Available from: https://doi.org/10.1016/S0140-6736(21)00213-0

   Full article — The Lancet

6. Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425. doi:10.1001/jama.2021.3224. Available from: https://doi.org/10.1001/jama.2021.3224

   Full article — JAMA

7. Rubino DM, Greenway FL, Khalid U, O’Neil PM, Rosenstock J, Sørrig R, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138-150. doi:10.1001/jama.2021.23619. Available from: https://doi.org/10.1001/jama.2021.23619

   Full article — JAMA

8. Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 2019;10:155. doi:10.3389/fendo.2019.00155. Available from: https://doi.org/10.3389/fendo.2019.00155

   Full article — Frontiers in Endocrinology

9. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-1439. doi:10.1152/physrev.00034.2006. Available from: https://doi.org/10.1152/physrev.00034.2006

   Full article — Physiological Reviews

10. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740-756. doi:10.1016/j.cmet.2018.03.001. Available from: https://doi.org/10.1016/j.cmet.2018.03.001

    Full article — Cell Metabolism

11. Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519. Available from: https://doi.org/10.1056/NEJMoa2107519

    Full article — New England Journal of Medicine

12. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038. Available from: https://doi.org/10.1056/NEJMoa2206038

    Full article — New England Journal of Medicine

13. Penn Medicine. Semaglutide sustains lower calorie intake for more than a year [Internet]. Philadelphia (PA): Penn Medicine; 2026 Jul 21. Available from: https://www.pennmedicine.org/news/semaglutide-still-has-benefits-after-one-year

    Penn Medicine — Semaglutide sustains lower calorie intake

14. U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss [Internet]. Silver Spring (MD): U.S. Food and Drug Administration. Available from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

    FDA — Concerns with unapproved GLP-1 drugs